Clinical Trial Details
— Status: Enrolling by invitation
Administrative data
| NCT number |
NCT05300373 |
| Other study ID # |
TR-ADA-009 |
| Secondary ID |
|
| Status |
Enrolling by invitation |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 3, 2021 |
| Est. completion date |
December 3, 2023 |
Study information
| Verified date |
March 2022 |
| Source |
TRPHARM |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study was designed as an observational, prospective, epidemiological screening study.
Patients who have been admitted to the center and whose lymphopenia and/or Immunoglobulin E
elevation has been detected in at least one examination in their medical history will be
included.
In accordance with the relevant legislation, patients are required to accept and sign the
Informed Consent Form regarding their participation in the study.
Current data that the physician has already questioned in his daily practice will be
collected from patients who have agreed to participate in the study, and a blood sample will
be taken from patients on Guthrie paper. This sample will be prepared by taking it from the
patient as the physician deems appropriate, dripping it into a special area designated on
Guthrie paper and drying it.
The test result will be sent to the researcher by e-mail. In case of formation of new
information for each patient, consultation will be provided by the responsible researcher.
Thus, the prevalence of ADA enzyme deficiency disease in patients with lymphopenia will be
evaluated. In addition, with this study, it will be scientifically demonstrated whether
lymphopenia is a parameter that facilitates early diagnosis of ADA patients.
Description:
Primary immunodeficiencies are encountered with signs and symptoms related to various
disciplines of medicine and are detected more often in our country than in other societies.
Severe Combined Immunodeficiencies (SCID) are a heterogeneous group of diseases caused by
hereditary errors in genes involved in the development and/or function of T, B, and sometimes
NK cells, which cause serious dysfunction of the immune system. The incidence is estimated at
1/100,000 live births in the USA. Although the exact incidence of inbreeding is not known in
our country, where inbreeding is common, it is expected that those who show autosomal
recessive transition will be more common, especially. Each step that is effective in the
emergence of an immune response creates the potential for a primary immunodeficiency disease.
Due to the development of molecular and cellular techniques, the possibility of prenatal
diagnosis has arisen with the detection of localization and mutations of the defective gene
in various immunodeficiencies. The recognition of these disorders by clinicians is important
for reducing long-term complications due to recurrent infections and preventing mortality
with appropriate treatment.
The frequency of SCID in our country is unknown. Unlike in Europe and America, SCID types,
which are autosomal recessive in our country, are considered to be the most common form due
to the high rates of inbreeding. The figure obtained by comparing the number of live babies
born in a year in Konya with the number of SCID cases diagnosed in the same year at the
Pediatric Immunology Clinic of the Meram Faculty of Medicine of Selcuk University, the only
primary immunodeficiency diagnostic center in the region, is 1/10,000. This preliminary study
shows that in our country this disease is much more common than in Europe and America. About
1,300 a year in our country.considering that 000 babies have been born, it should be expected
that 140 new cases of SCID should be encountered every year. The number of cases diagnosed in
our country is much lower than this figure.
To date, more than 20 genetic defects have been identified that cause SCID. All known genetic
defects disrupt the development of cells of the immune system, causing combined
immunodeficiency. One of them, the ADA defect, is also a metabolic disease, due to which
there is a lack of enzymes.
ADA catalyzes the deamination of purine nucleosides adenosine (Ado) and 2'-deoxyadenosine
(dAdo), which are produced during the degradation and transformation of RNA and DNA. ADA is a
cleansing enzyme; it detoxifies purines. In ADA deficiency, 2'-deoxyadenosine (dAdo) is
phosphorylated and converted into deoxyadenosine triphosphate (dATP). Accumulation of DATP
disrupts DNA repair and replication. In ADA deficiency, a high percentage of dATP
accumulates, especially in erythrocytes and lymphocytes. Increased levels of adenosine break
down the wall of the lymphocyte. It inhibits the development of lymphocytes in the thymus. A
kind of lymphocyte intoxication occurs. It leads to a severe form of lymphopenia.
Approximately 10-20% of AKIS are diagnosed as ADA enzyme deficiency. It shows an autosomal
recessive transition. Your gene is 20. it is localized on the long arm of the chromosome.
Clinically, there are early and late onset types. Classic-early onset ADA deficiency:
Although normal at birth, patients present with infections seen from the first months of
life, resulting in death if left untreated. In addition to the SCI table, neuro-developmental
disorders, sensorineural hearing loss and/or skeletal abnormalities have also been reported
in these patients. Although hematopoietic stem cell transplantation, enzyme replacement
therapy and gene therapy are treatment approaches that provide cure, early diagnosis
determines the prognosis.
Late onset ADA deficiency: Patients may present with recurrent infections, autoimmunity,
human papillomavirus (HPV) infections at an older age, even in adulthood. Lymphopenia is an
invariable finding. High IgE and eosinophilia may be observed. In these cases, residual
enzyme activity due to the type of mutation causes a late onset. This phenotype accounts for
10-15% of all cases of ADA deficiency.
Diagnosis: ADA enzyme deficiency is included in severe combined immunodeficiencies and is
observed with lymphopenia and infections. The diagnosis is made by measuring the activity of
the enzyme ADA in erythrocytes or lymphocytes in patients with suspected clinical and
laboratory features (such as lymphopenia). By mutation analysis, a gene defect is shown.
However, T-cell receptor excision circles (TREC) test is used for early diagnosis. However,
since the TREC test is found to be normal at birth in late-onset patients, screening that
leads patients to an early diagnosis can only be achieved by measuring ADA metabolites.
Although studies are continuing for SCID, which has not yet been included in the screening
program in our country, the tandem mass spectrometer, which can be used to diagnose ADA
deficiency, is used in newborn screening programs for metabolic diseases. Studies of newborn
screening with a tandem mass spectrometer for ADA and PNP deficiencies, which is also a
metabolic disease, began after 2010, and it has been shown that this method is a low-cost and
reliable method. Early and late onset ADA deficiency cases can be detected with sensitivity
and specificity reaching 100% with this method.
Importance of early diagnosis: In Early Onset ADA deficiency, patients usually consult a
doctor with signs of infections. The fact that infections are already common in the dairy
childhood age group makes diagnosis difficult. If there is no similar case in the family that
has been diagnosed before, or if this is not paid attention to in the history, the diagnosis
of the cases is delayed. In late-onset ADA deficiency, the diagnosis is much more difficult.
Low awareness of the disease and its symptoms usually results in these cases not being
diagnosed, not being able to get effective treatment, and organ damage. For this reason,
early diagnosis is very important in terms of quality of life as well as vital importance.
